Three-day standard dose cytarabine could induce an M4Eo patient into complete remission.
Higuchi
T
T
Division of Hematology, Showa University Fujigaoka Hospital, Yokohama, Japan.
Saito
F
F
Mori
H
H
Omine
M
M
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use*; D006801:Humans; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000188:drug therapy*; D013274:Stomach Neoplasms / Q000473:pathology*
D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine